|Assessment Status||Full HTA Assessment|
|Indication||For the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.|
|NCPE assessment re-commenced||23/01/2007|
|NCPE assessment completed||03/04/2007|
|NCPE assessment outcome||Reimbursement recommended.|
Natalizumab could be considered borderline cost effective in the Irish healthcare setting. In view of the uncertainty surrounding some of the ICERs a follow up review is advised. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.